Nexalin Technology (Nexalin Technology) Change In Receivables : $0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Nexalin Technology Change In Receivables?

Nexalin Technology's change in receivables for the quarter that ended in Mar. 2024 was $0.01 Mil. It means Nexalin Technology's Accounts Receivable declined by $0.01 Mil from Dec. 2023 to Mar. 2024 .

Nexalin Technology's change in receivables for the fiscal year that ended in Dec. 2023 was $-0.00 Mil. It means Nexalin Technology's Accounts Receivable increased by $0.00 Mil from Dec. 2022 to Dec. 2023 .

Nexalin Technology's Accounts Receivable for the quarter that ended in Mar. 2024 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Nexalin Technology's Days Sales Outstanding for the three months ended in Mar. 2024 was 4.62.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Nexalin Technology's liquidation value for the three months ended in Mar. 2024 was $1.72 Mil.

Nexalin Technology Change In Receivables Historical Data

The historical data trend for Nexalin Technology's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nexalin Technology Change In Receivables Chart

Nexalin Technology Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Change In Receivables

-0.01

Nexalin Technology Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial									-	-0.01	-	0.01	0.01

Nexalin Technology Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Nexalin Technology (NAS:NXL) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Nexalin Technology's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.004	/	0.079	*	91
=	4.62

2. In Ben Graham's calculation of liquidation value, Nexalin Technology's accounts receivable are only considered to be worth 75% of book value:

Nexalin Technology's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	2.144	-	0.507	+	0.75 * 0.004	+	0.5 * 0.154
=	1.72

Nexalin Technology Change In Receivables Related Terms

Thank you for viewing the detailed overview of Nexalin Technology's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Nexalin Technology (Nexalin Technology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nexalin Technology Inc (NAS:NXL) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

1776 Yorktown, Suite 550, Houston, TX, USA, 77056

Website

https://www.nexalin.com

Nexalin Technology Inc design and develop innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy.

Executives

Marilyn Elson	10 percent owner, officer: Ms. Elson serves as CFO	32 CAMLET COURT, ROSELAND NJ 07068
Rick Morad	director	6331 CHAGRIN RIVER ROAD, BENTLEYVILLE OH 44022
Mark White	director, officer: President/CEO	1776 YORKTOWN STREET, SUITE 550, HOUSTON TX 77056
David Owens	director, officer: Chief Medical Officer	4545 HARRIS TRAIL NW, ATLANTA GA 30327
Alan Kazden	director	3435 CONSUELO DRIVE, CALABASAS CA 91302
Leonard Osser	other: Spouse
Ben Hu	director	7021 EDGERTON ROAD, NORTH ROYALTON OH 44133